WESTBROOK, Maine, Jan. 8, 2018 /PRNewswire/ -- IDEXX Laboratories,
Inc. (NASDAQ: IDXX) and Applied BioCode (6598:Taipei) today
announced that they have entered into an exclusive global agreement
to bring Applied BioCode's digital multiplex platform to IDEXX
Reference Laboratories customers. IDEXX anticipates the technology
will be commercially available starting in 2019. Applied BioCode is
a California-headquartered
diagnostics company that designs, develops, manufactures, and
markets systems for highly multiplexed assays.
"IDEXX's market-leading innovation is at the core of our
strategy," said Jonathan Ayers,
Chairman and Chief Executive Officer of IDEXX Laboratories.
"Implementation of Applied BioCode's technology supports our vision
for margin expansion, and it will allow us to offer customers
expanded test menu breadth and menu customization for each patient
sample submitted to IDEXX Reference Laboratories in the future.
This is consistent with our commitment to provide the most
comprehensive, cost-effective, and timely diagnostic picture for
our customers and their patients. This proprietary technology
platform will also likely have applications in our other animal
health diagnostic markets."
Paired with IDEXX's proprietary assays and reagents, Applied
BioCode's technology enables the development of an ultra-high
sensitivity immunoassay platform. Immunoassay is the detection
technology used on platforms such as IDEXX SNAP® tests
for applications as diverse as vector-borne disease and
parasitology as well as for both sick and preventive care uses.
"Applied BioCode is thrilled to introduce our technology to
veterinary medicine with IDEXX, enabling veterinarians to benefit
from our advanced multiplexing capabilities," said Winston Ho, President of Applied BioCode. "We
look forward to working with the IDEXX team to implement our
platform at its reference laboratories."
For more information about IDEXX Reference Laboratories, visit
www.idexx.com.
About IDEXX Laboratories
IDEXX Laboratories, Inc. is a member of the S&P
500® Index and is a leader in pet healthcare innovation,
serving practicing veterinarians around the world with a broad
range of diagnostic and information technology-based products and
services. IDEXX products enhance the ability of veterinarians to
provide advanced medical care, improve staff efficiency and build
more economically successful practices. IDEXX is also a worldwide
leader in providing diagnostic tests and information for livestock
and poultry and tests for the quality and safety of water and milk.
Headquartered in Maine, IDEXX
Laboratories employs more than 7,000 people and offers products to
customers in over 175 countries. For more information about IDEXX,
visit www.idexx.com.
About Applied BioCode
Applied BioCode is a publicly traded diagnostic company that
develops, manufactures, and markets Barcoded Magnetic Beads (BMBs)
and detection systems to facilitate development of highly
multiplexed nucleic acids or protein detection assays. The BMB
technology offers up to 4,096 unique digital barcodes for multiplex
analysis with unmatched decoding accuracy. Their easy-to-use
BioCode systems employ steady state detection without requiring
flow cytometers that are prone to channel blockage or sample cross
contamination. The system is well suited for clinical diagnostic
applications, such as detection of infectious pathogens, drug
resistance markers, cancer markers and mutation analysis, as well
as specific applications for the life science research and
agricultural testing markets. For more information, visit the
company's website at www.apbiocode.com.
Note Regarding Forward-Looking Statements
This news release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by the use of
words such as "expects," "may," "anticipates," "intends," "would,"
"will," "plans," "believes," "estimates," "should," and similar
words and expressions. These forward-looking statements are based
on management's current expectations and beliefs, as well as a
number of assumptions concerning future events. These
forward-looking statements involve known and unknown risks and
uncertainties that may cause the Company's actual results,
performance or achievements to be materially different from those
expressed or implied by these forward-looking statements. IDEXX
assumes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. Readers are advised to review IDEXX's filings with the
United States Securities and Exchange Commission (which are
available from the SEC's EDGAR database
at www.sec.gov and via IDEXX's website
at www.idexx.com).
CONTACTS:
Media Relations
Robin Woodcock
207-632-8027
robin-woodcock@idexx.com
Investor Relations
Kerry Bennett
207-556-8155
kerry-bennett@idexx.com
View original
content:http://www.prnewswire.com/news-releases/idexx-to-introduce-applied-biocodes-innovative-multiplex-technology-across-global-reference-laboratory-network-300578281.html
SOURCE IDEXX Laboratories, Inc.